中國醫藥(600056.SH):擬與集團數科公司設新公司、開展醫藥和醫療器械等領域的數字化建設
格隆匯7月20日丨中國醫藥(600056.SH)公佈,公司第八屆董事會第24次會議決議,審議通過了《關於與關聯方合資新設公司的議案》。
為進一步打造公司核心競爭優勢,更好適應行業數字變革要求,有效提升管控能力,公司擬與通用技術集團數字智能科技有限公司(“集團數科公司”)簽署《股權合作協議》,雙方擬全部以現金方式出資,成立“通用技術醫藥健康數智科技有限公司”(暫定,以工商登記機關登記的名稱為準。“新公司”),開展醫藥和醫療器械等領域的數字化建設。新公司註冊資本1000萬元,其中:公司出資700萬元,持股70%;集團數科公司出資300萬元,持股30%。
實施該項目,可發揮公司產業資源優勢,提升數字化水平,服務公司整體戰略,引領高質量發展。新公司初期主要承擔公司商業板塊、全級次管控平台系統的建設,後續將逐步覆蓋公司貿易板塊及工業板塊,面向醫療機構逐步打造和完善覆蓋醫藥、醫療器械、患者服務、技術服務等多領域全方位的數字化供應鏈支持平台,為醫療機構賦能,形成公司的核心能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.